Therapeutic vaccination for cancer: The potential value of mycobacterial products

John L. Stanford, C. A. Stanford, Babak Baban, J. M. Grange

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Attempts to treat cancer by various forms of immunotherapy were first made over a century ago. Initial attempts were based on the empirical use of bacterial toxins and probably acted by inducing tumour necrosis factor, together with type 2 cytokines. Following the discovery of tumour-specific antigens in 1953, many attempts were made to stimulate immune defences non-specifically, and the use of Bacille Calmette-Guerin (BCG) figured prominently in these attempts but with very variable responses. In recent years, advances in knowledge of the molecular and cellular basis of both cancer and the immune system have led to more rational approaches. In particular, the finding that there are several quite distinct cytokine-mediated types of immune reactivity has led to attempts to selectively enhance the reactions most effective in destroying cancer cells and down-regulating responses which may antagonise the effective reactions. Although type 2 cytokine mediated responses may be effective in some situations, there is increasing evidence that effective antitumour immune responses are likely to be mediated by type 1 cytokines. While the commonly used living BCG vaccine is a powerful adjuvant it is able, depending on prior environmental sensitisation, to evoke either Th1 or Th2 responses and may thus be a two-edged sword in cancer immunotherapy. Recently investigations indicate that another mycobacterial preparation, heat-killed Mycobacterium vaccae, is a more reliable Th1 adjuvant and preliminary clinical trials indicate beneficial effects in melanoma, and cancer of the prostate and lung. More extensive controlled studies are currently being conducted to confirm these findings.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalInternational Journal of Pharmaceutical Medicine
Volume13
Issue number4
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Vaccination
Cytokines
Immunotherapy
Neoplasms
Bacterial Toxins
BCG Vaccine
Neoplasm Antigens
Therapeutics
Mycobacterium
Immune System
Melanoma
Lung Neoplasms
Prostatic Neoplasms
Tumor Necrosis Factor-alpha
Hot Temperature
Clinical Trials

Keywords

  • BCG
  • Cancer
  • Coley toxins
  • Immunotherapy
  • Mycobacteria vaccae

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic vaccination for cancer : The potential value of mycobacterial products. / Stanford, John L.; Stanford, C. A.; Baban, Babak; Grange, J. M.

In: International Journal of Pharmaceutical Medicine, Vol. 13, No. 4, 01.01.1999, p. 191-195.

Research output: Contribution to journalArticle

Stanford, John L. ; Stanford, C. A. ; Baban, Babak ; Grange, J. M. / Therapeutic vaccination for cancer : The potential value of mycobacterial products. In: International Journal of Pharmaceutical Medicine. 1999 ; Vol. 13, No. 4. pp. 191-195.
@article{2e3bb9bad3c7494db02543ea0422b6b8,
title = "Therapeutic vaccination for cancer: The potential value of mycobacterial products",
abstract = "Attempts to treat cancer by various forms of immunotherapy were first made over a century ago. Initial attempts were based on the empirical use of bacterial toxins and probably acted by inducing tumour necrosis factor, together with type 2 cytokines. Following the discovery of tumour-specific antigens in 1953, many attempts were made to stimulate immune defences non-specifically, and the use of Bacille Calmette-Guerin (BCG) figured prominently in these attempts but with very variable responses. In recent years, advances in knowledge of the molecular and cellular basis of both cancer and the immune system have led to more rational approaches. In particular, the finding that there are several quite distinct cytokine-mediated types of immune reactivity has led to attempts to selectively enhance the reactions most effective in destroying cancer cells and down-regulating responses which may antagonise the effective reactions. Although type 2 cytokine mediated responses may be effective in some situations, there is increasing evidence that effective antitumour immune responses are likely to be mediated by type 1 cytokines. While the commonly used living BCG vaccine is a powerful adjuvant it is able, depending on prior environmental sensitisation, to evoke either Th1 or Th2 responses and may thus be a two-edged sword in cancer immunotherapy. Recently investigations indicate that another mycobacterial preparation, heat-killed Mycobacterium vaccae, is a more reliable Th1 adjuvant and preliminary clinical trials indicate beneficial effects in melanoma, and cancer of the prostate and lung. More extensive controlled studies are currently being conducted to confirm these findings.",
keywords = "BCG, Cancer, Coley toxins, Immunotherapy, Mycobacteria vaccae",
author = "Stanford, {John L.} and Stanford, {C. A.} and Babak Baban and Grange, {J. M.}",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "191--195",
journal = "Pharmaceutical Medicine",
issn = "1178-2595",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Therapeutic vaccination for cancer

T2 - The potential value of mycobacterial products

AU - Stanford, John L.

AU - Stanford, C. A.

AU - Baban, Babak

AU - Grange, J. M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Attempts to treat cancer by various forms of immunotherapy were first made over a century ago. Initial attempts were based on the empirical use of bacterial toxins and probably acted by inducing tumour necrosis factor, together with type 2 cytokines. Following the discovery of tumour-specific antigens in 1953, many attempts were made to stimulate immune defences non-specifically, and the use of Bacille Calmette-Guerin (BCG) figured prominently in these attempts but with very variable responses. In recent years, advances in knowledge of the molecular and cellular basis of both cancer and the immune system have led to more rational approaches. In particular, the finding that there are several quite distinct cytokine-mediated types of immune reactivity has led to attempts to selectively enhance the reactions most effective in destroying cancer cells and down-regulating responses which may antagonise the effective reactions. Although type 2 cytokine mediated responses may be effective in some situations, there is increasing evidence that effective antitumour immune responses are likely to be mediated by type 1 cytokines. While the commonly used living BCG vaccine is a powerful adjuvant it is able, depending on prior environmental sensitisation, to evoke either Th1 or Th2 responses and may thus be a two-edged sword in cancer immunotherapy. Recently investigations indicate that another mycobacterial preparation, heat-killed Mycobacterium vaccae, is a more reliable Th1 adjuvant and preliminary clinical trials indicate beneficial effects in melanoma, and cancer of the prostate and lung. More extensive controlled studies are currently being conducted to confirm these findings.

AB - Attempts to treat cancer by various forms of immunotherapy were first made over a century ago. Initial attempts were based on the empirical use of bacterial toxins and probably acted by inducing tumour necrosis factor, together with type 2 cytokines. Following the discovery of tumour-specific antigens in 1953, many attempts were made to stimulate immune defences non-specifically, and the use of Bacille Calmette-Guerin (BCG) figured prominently in these attempts but with very variable responses. In recent years, advances in knowledge of the molecular and cellular basis of both cancer and the immune system have led to more rational approaches. In particular, the finding that there are several quite distinct cytokine-mediated types of immune reactivity has led to attempts to selectively enhance the reactions most effective in destroying cancer cells and down-regulating responses which may antagonise the effective reactions. Although type 2 cytokine mediated responses may be effective in some situations, there is increasing evidence that effective antitumour immune responses are likely to be mediated by type 1 cytokines. While the commonly used living BCG vaccine is a powerful adjuvant it is able, depending on prior environmental sensitisation, to evoke either Th1 or Th2 responses and may thus be a two-edged sword in cancer immunotherapy. Recently investigations indicate that another mycobacterial preparation, heat-killed Mycobacterium vaccae, is a more reliable Th1 adjuvant and preliminary clinical trials indicate beneficial effects in melanoma, and cancer of the prostate and lung. More extensive controlled studies are currently being conducted to confirm these findings.

KW - BCG

KW - Cancer

KW - Coley toxins

KW - Immunotherapy

KW - Mycobacteria vaccae

UR - http://www.scopus.com/inward/record.url?scp=0032822849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032822849&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032822849

VL - 13

SP - 191

EP - 195

JO - Pharmaceutical Medicine

JF - Pharmaceutical Medicine

SN - 1178-2595

IS - 4

ER -